NCT00710450

Brief Summary

Subjects with either allergic asthma or allergic rhinitis will be recruited to obtain blood. This blood will be used to be stimulated with to whatever the patient allergic. In the laboratory, this stimulated blood will be measured for histamine, leukotrienes, IL-13 and IL-3. These are chemicals responsible for allergy symptoms.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
15

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started May 2008

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2008

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

July 1, 2008

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 4, 2008

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2011

Completed
Last Updated

September 23, 2011

Status Verified

September 1, 2011

Enrollment Period

3.3 years

First QC Date

July 1, 2008

Last Update Submit

September 22, 2011

Conditions

Allergic AsthmaAllergic Rhinitis

Keywords

IL13leukotrienehistamineIL4Must be allergic asthma or allergic rhinitis

Outcome Measures

Primary Outcomes (1)

  • Histamine Release

    during the assay portion.

Secondary Outcomes (1)

  • Cytokine release. IL-13, IL-4 and leukotriene

    assay portion

Study Arms (2)

1

Allergic Asthma

2

Allergic Rhinitis

Eligibility Criteria

Age12 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Allergic rhinitis or allergic asthma, age 13+

You may qualify if:

  • Allergic asthma or allergic rhinitis
  • age 12+

You may not qualify if:

  • smokers

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Creighton University Medical Center

Omaha, Nebraska, 68131, United States

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Supernatents from stimulation assays will be kept for batch assay.

MeSH Terms

Conditions

Rhinitis, Allergic

Condition Hierarchy (Ancestors)

RhinitisNose DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityOtorhinolaryngologic DiseasesHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 1, 2008

First Posted

July 4, 2008

Study Start

May 1, 2008

Primary Completion

September 1, 2011

Study Completion

September 1, 2011

Last Updated

September 23, 2011

Record last verified: 2011-09

Locations

US(1)